Pieris Pharmaceuticals, Inc.
NASDAQ:PIRS
Overview | Financials
Company Name | Pieris Pharmaceuticals, Inc. |
Symbol | PIRS |
Currency | USD |
Price | 17.3 |
Market Cap | 22,840,152 |
Dividend Yield | 0% |
52-week-range | 6.2 - 23.2 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Stephen S. Yoder J.D. |
Website | https://www.pieris.com |
An error occurred while fetching data.
About Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD